Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in Macular Edema Secondary to BRVO
CTR20191559Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2019
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in branch retinal vein occlusion (BRVO), sponsored by Novartis. Started Aug 2019; status: terminated.
02
Drugs
brolucizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on CTR20191559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191559.